Medicines New Zealand Unveils 2022 Transfer of Value Reports to Enhance Transparency

By Staff Writer

August 30, 2023

Medicines New Zealand is delighted to announce the launch of the 2022 Transfer of Value reports. These reports, representing the organisation’s second annual publication, offer a transparent snapshot of the financial interactions between biopharmaceutical companies and healthcare professionals. This initiative underscores our unwavering commitment to transparency and ethical standards within the industry.

Dr Graeme Jarvis, CEO of Medicines New Zealand, remarked on the release, “This information is what the joint project between industry and healthcare practitioners was designed to deliver.”

The reports aim to shed light on the financial relationships and interactions between biopharmaceutical companies and healthcare professionals. They seek to bolster transparency and uphold ethical standards within the industry.

“Public reporting of payments made by the biopharmaceutical industry to healthcare professionals is the right thing to do from a transparency perspective,” said Dr Jarvis. “This commitment allows patients and the public to gain insight into the nature of these interactions and have confidence in the ethical standards and patient-centric approach of healthcare professionals in New Zealand.”

The 2022 Transfer of Value reports provide a comprehensive overview of the financial interactions between Medicines New Zealand member companies and healthcare professionals. These interactions include sponsorships for healthcare providers to attend medical education events and conferences, which ultimately benefit patient care and contribute to the continuous improvement of healthcare practices.

Medicines New Zealand invites all interested parties to access the Transfer of Value reports from its member companies. The reports serve as a valuable resource for those seeking a deeper understanding of the financial relationships that drive advancements in patient care.

Reference url

Recent Posts

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

value-based drug pricing
      

Optimizing Value-Based Drug Pricing in Japan with MARIE Framework

🔍 Are we pricing drugs based on true value?

The introduction of the MARIE framework in Japan revolutionizes value-based drug pricing by considering not just costs, but the actual benefits drugs provide to patients and society. This innovative approach significantly adjusts prices based on updated clinical data and allows for more equitable access to therapies.

Curious about how MARIE can reshape drug pricing and pharmaceutical innovation? Dive into the full article for insights!

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.